Supply:Ferric hydroxide polymaltose contains 100mg of elemental iron/Tab (FERRUM HAUSMANN CHEWABLER)
Ferro sulfate 324mg contains 65mg of elemental iron/S.C.Tab (FERROUS SULFATER)
Ferrous fumarate50mg/S.C.Tab(BLOODFULLR)
Fe150mg/Cap(NIFEREX-150R)
Ferrous sulfat 160mg, Folic acid 400 mg contains 50 mg of element iron /Tab (SLOW-FE FOLICR)
Use:Iron deficiency due to chronic blood loss, pregnancy, premature babies, severe pernicious anemia.
Contraindication:Patients receiving repeated blood transfusions or with anemias not produced by iron deficiency; with iron-storage or iron-absorption diseases, haemoglobinopathies, or exisitng GI disease.
Adverse effect:Therapeutic dose may cause mild GI discomfort, diarrhea, vomiting; side effect is reduced by taking it with or immediately after food; constipation (large dose > 180mg iron/day), irritant and corrosive effects on GI mucosa, and necrosis and perforation may occur.
Usual dosage:1. Usual therapeutic dosage : Adults: PO 50-100mg of elemental iron TID; child: elemental iron 4-6mg/kg/day in 3 divided doses. 2. Prevent iron deficiency: pregnant women: 30mg of iron, not breast-fed infants: 1mg/kg/day, max 10mg/day; low-birth-weight infants: 2mg/kg/day for 2 months, max 15mg/day; more than 10-year old child: male : 2mg/day, female 5mg/day.
Anticoagulants
ACETYLSALICYLIC ACID C
Supply:100mg/Tab(TAPALR), 100mg/E.M.Cap(BOKEYR
Use:Muscular and vascular pains, headache, dentalgia, arthritis, bursitis, rheumatoid arthritis, rheumatic fever, inflammatory joints condition. Fever and discomfort of cold, and as an anticoagulant (anti-thrombotic action).
Contraindication:Hypersensitivity to salicylate, active peptic ulceration, hemophilia, severe hepatic damage and pregnancy women.
Adverse effect:Gastric ulceration, dyspepsia, heartburn, hemorrhage, skin eruptions, tinnus, decreased hearing and vertigo.
Usual dosage:Adults: analgesia & antipyresis: 0.6gm Q4H or 0.3g Q3H. anti-inflammatory: 4 gm/daily. Anticoagulant: 325mg TID or QID. Child: 50-75mg/kg/day.
ENOXAPARIN SOD. C
Supply:100mg/ml 0.6ml/Bot(CLEXANER)
Use:Prophylactic treatment of venous thromboembolic disease, particularly in orthopaedic & general surgery. Treatment of established DVT. Prevention of thrombosis in extracorporeal circulation during haemodialysis. Unstable angina, Non-Q-wave myocardial infarction
Contraindication:History of thrombocytopenia during enoxaparin therapy. Hemorrhagic tendencies, organic lesion with tendency to bleed, major blood clotting disorder. Acute infectious endocarditis, hemorrhagic stroke syndrome, acute GI ulcer.
Adverse effect:Hemorrhagic symptoms, thrombocytopenia (rare), hematomas & skin necrosis at inj site; skin allergies or systemic allergic reactions
HEPARIN C
Supply:1000U/ml 5ml/Amp(SODIUM HEPARINR)
5000U/5ml/Vial(HEPARIN LEOR)
Use:Low doses for prophylaxis of postoperative venous thrombosis, high doses to treat established thrombosis.
Contraindication:Tendency of bleeding, in the presence of active peptic ulceration, or severe indigestion, in severe renal or heaptic disease. Hypertension, increases the risk of cerebral haemorrhage. In subacute bacterial endocarditis, embolism is not prevented, and may be accompanied by haemorrhage, especially in the brain.
Adverse effect:Bleeding (after surgery), transient alopecia, allergy (rare), mild thrombocytopenia.
Usual dosage:SC, intermittent IV infusion, continuous IV infusion. Established thrombosis: IV 5000 IU, followed by either 1500 IU per hour given by constant rate infusion pump or alternatively 35000 IU in one liter N/S (stable for 24 hours) infused over 24 hours. i.e. a daily dose of about 4000 IU or 10000 IU through an indwelling IV cannula Q6H. Prevention of thrombosis: 5000 IU SC 2 hours before operation, repeated Q8-12H until patient is ambulatory.
TICLOPIDINE B
Supply:100mg/F.C.Tab(LICODINR), 250mg/Tab(TICLOPIDINER)
Use:Ticlopidine is an antiplatelet drug with a mechanism of action different from that of aspirin or other nonsteroidal antiinflammatory drugs. Ticlopidine decreases platelet aggregation, circulating platelet aggregates, and prolongs bleeding time. It may be useful in the prevention of thromboembolic disorders, cardiovascular mortality, stroke, myocardial infarction, and vaso-occlusive sickle cell crisis. The drug may also be useful in maintaining graft patency or access sites for hemodialysis.
Contraindication:Hypersensitivity, active bleeding disorders, neutropenia or thrombocytopenia, severe liver impairment. Ticlopidine should be discontinued if the absolute neutrophil count falls below 1200/mm3 or if the platelet count falls below 80,000/mm3.
Adverse effect:Neutropenia, thrombocytopenia, leukopenia, agranulocytosis, pancytopenia, thrombocytopenic purpura, hemorrhage, ecchymosis, epostaxis, menorrhagia, gastro-intestinal bleeding, dizziness, nausea, vomiting, abdominal cramps, dyspepsia, flatulence, anorexia, liver damage, rash, urticaria.
Usual dosage:PO 250mg BID, maintain patency in patients on hemodialysis: 200mg QD, duration ranged from 9 days (post-operative thrombosis) to 6 months.
WARFARIN SOD. D
Supply:5mg/Tab(COUMADINR)
Use:Venous thrombosis or pulmonary embolism, and in patients with atrial fibrillation, prosthetic heart valves, rheumatic valvular disease and transient ischaemic attacks, prevention of postoperative deep vein thrombosis.
Usual dosage:PO: Initial daily dosage is 40-60mg; the average maintenance dose is 2-10mg daily, based on the patient's prothrombin time response.
Hemostatics
DESMOPRESSIN B
Supply:0.1mg/Tab(MINIRINR)
Use:Central (neurogenic) diabetes insipidus, for urine concentration test. In addition, desmopressin may be useful in increasing plasma levels of factor VIII activity in patients with hemophilia A or von Willebrand's disease.
Contraindication:Hypersensitivity to desmopressin, patients with coronary insufficiency and or hypertension.
Adverse effect:Adverse effects include hypotension, headache, psychosis, seizures, water retention and hyponatremia, abdominal cramps, vulval pain, nasal congestion, rhinitis, flushing, local dermatologic effects following injection, and hypersensitivity reactions.
Usual dosage: The initial oral dose is 0.05 mg twice daily titrated to clinical response; the usual range is 0.1 to 0.8 mg daily.
TRANEXAMIC ACID B
Supply:250mg/Cap(TRANSAMINR),
50mg/ml 20ml/Amp(TRANEXAMICR)
Use:Antiplasmin (antifibrinolytic) agent. Used in haemorrhage caused by administration of plasminogen activators (streptokinase, urokinase), obstetric complications, and in hyperplasminaemic states.
Contraindication:In the presence of an underlying thrombosing state.
Adverse effect:Diarrhea, headache, hypotension, heartburn, dizziness, pruritus, erythema, skin rash , nausea, nasal stuffiness, diuresis, muscle pain, weakness, intrarenal obstruction.
Usual dosage:PO 1-1.5gm BID-TID, dosage reduced in renal failure.
IV, usual dose is 0.5 to 1g (10 to 15mg/kg) given 2 to 3 times daily, starting immediately after surgery; and after a few days, 1 to 1.5g orally 3 to 4 times daily.
PHYTOMENADIONE(VITAMIN K1) C
Supply:10mg/1ml/Amp(KATIMIN "1"R)
Use:Hypoprothrombinaemia due to oral anticoagulants, antibacterials and salicylates; hemorrhagic disease of the newborn.
Adverse effect:Severe reactions (flushing, dyspnea, chest pain) and occasionally deaths have occurred after IV, possibly due to emulsifier; inject site allergy.
Usual dosage:IM, SC is preffered; in emergency, direct IV push not exceeding 1mg/min, or IV infusion. Dose, route, duration of therapy are dependent on patient's requirements and regulated by repeated determinations of prothrombin time. Newborns: 0.5-1.0mg IM or SC, to correct excessively long prothrombin time. In adults: 2.5-25mg or up to 50mg given initially, subsequent doses be individualized on the basis of response.
Now: 
